Paysign, INC

Paysign, Inc. announced first quarter 2026 financial results, showcasing a 50.8% year-over-year revenue increase to $28.04 million, driven by significant growth in its patient affordability and plasma revenue segments, alongside substantial margin expansion.

Paysign, Inc. reported record full-year 2025 financial results, driven by a 40.5% revenue increase and significant margin expansion, primarily from its patient affordability solutions.

Paysign, Inc. announced strong third quarter 2025 financial results with record revenue and improved profitability, leading to an upward revision of its full-year 2025 guidance.

Paysign, Inc. has reached a settlement in multiple stockholder derivative actions, agreeing to implement significant corporate governance reforms and pay $607,500 in legal fees.

Paysign, Inc. reported record second quarter 2025 revenues of $19.08 million, a 33.1% increase year-over-year, driven by strong growth in its pharma patient affordability business.

Paysign, Inc. has announced a change in its independent registered public accounting firm from Moss Adams LLP to Baker Tilly US, LLP, effective June 3, 2025, due to a merger between the two accounting firms.

Paysign, Inc. announced a significant increase in total revenues and net income for the first quarter of 2026, driven by substantial growth in its pharma and plasma industries segments.

Paysign, Inc. reported a significant increase in Q3 2025 net income and revenue, driven by robust growth in its pharma patient affordability programs and expansion in plasma centers.

Paysign, Inc. reported a significant increase in net income and gross profit for Q2 2025, driven by robust growth in its pharma patient affordability programs.

Paysign's Q1 2025 net income surged to $2.59 million, driven by significant growth in the pharma industry, despite a decrease in plasma revenue.

Paysign's Q3 2024 results show significant revenue growth, particularly in the pharma and plasma sectors, leading to increased profitability.

Paysign Inc. announced a significant increase in revenue and net income for Q2 2024, fueled by growth in its plasma and pharmaceutical payment solutions.

Paysign, Inc. (PAYS) reported significant revenue and net income growth in 2025, fueled by expansion in its pharmaceutical and plasma industry programs and the acquisition of Gamma Innovation LLC.

Paysign's 2024 10-K filing reveals a 23.5% increase in total revenue, fueled by significant growth in the pharma and plasma industries, alongside strategic investments in technology and compliance.

Paysign Inc. saw a significant 24.3% increase in revenue in 2023, primarily driven by growth in its plasma and pharmaceutical sectors.

Dennis L Triplett, a Director of Paysign, Inc., received 20,000 shares of common stock on May 8, 2026.

Jeffrey B Newman, a Director of Paysign, Inc., received 20,000 shares of common stock on May 8, 2026.

Bruce A Mina, a Director of Paysign, Inc., sold 20,000 shares of common stock on May 8, 2026.

Daniel R Henry, a Director of Paysign, Inc., received 20,000 shares of common stock on May 8, 2026.

Mark Newcomer, CEO, a Director and 10% owner of Paysign, Inc., sold 50,000 shares of common stock on July 29, 2026 for $9.38 per share.

Joan M Herman, EVP, Operations and a Director of Paysign, Inc., sold 59,904 shares of common stock on July 15, 2026.

Paysign, Inc. announced its 2026 Annual Meeting of Stockholders to elect directors and ratify its independent auditor, Baker Tilly US, LLP, following a merger.

PaySign, Inc. has filed a definitive proxy statement with the SEC.

Paysign, Inc. announces its 2025 annual meeting of stockholders to be held on May 7, 2025, featuring proposals including director elections, executive compensation advisory votes, and auditor ratification.

PaySign Inc. has filed a definitive proxy statement with the SEC, providing information for shareholders regarding upcoming decisions.

Paysign, Inc. has released its definitive proxy statement, outlining the agenda and procedures for its 2024 annual meeting of stockholders to be held on May 3, 2024.

Topline Capital Management, LLC, along with Collin McBirney and Topline Capital Partners, LP, has filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.9% of Paysign, Inc.'s common stock.